Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Employment agrmnt Appointed CFO Quarterly results CC transcript Credit agrmnt [a] Acq. announced
|
Forest Laboratories, LLC (FRX)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/03/2014 |
8-K
| Form 8-K - Current report |
07/02/2014 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs:
|
"Second Supplemental Indenture, between Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Second Supplemental Indenture, between Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Second Supplemental Indenture, between Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Third Supplemental Indenture, among Actavis plc, Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Third Supplemental Indenture, among Actavis plc, Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee",
"Third Supplemental Indenture, among Actavis plc, Tango Merger Sub 2 LLC and Wells Fargo Bank, National Association, as trustee" |
|
07/02/2014 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
06/18/2014 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits |
06/13/2014 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs:
|
"First Supplemental Indenture, to the Indenture, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"First Supplemental Indenture, to the Indenture, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"First Supplemental Indenture, to the Indenture, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Waiver and Amendment, to the Registration Rights Agreements and January 31, 2014, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Forest Laboratories, Inc. Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes Release Date:" |
|
06/09/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
05/28/2014 |
8-K
| Other Events |
05/22/2014 |
8-K
| Other Events, Financial Statements and Exhibits |
05/20/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
04/29/2014 |
8-K
| Quarterly results |
04/28/2014 |
8-K
| Acquisition/merger/asset purchase announced
Docs:
|
"Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Revenue Rights Purchase Agreement, by and between Forest Laboratories, Inc. and RPI Finance Trust",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty",
"E-mail, from Brenton L. Saunders, the Chief Executive Officer of Forest Laboratories, Inc., to employees of Forest Laboratories, Inc",
"Investor Presentation",
"Transcript" |
|
04/28/2014 |
8-K
| Acquisition/merger/asset purchase announced
Docs:
|
"Agreement and Plan of Merger, by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc",
"Form of Contingent Value Rights Agreement by and between Forest Laboratories, Inc., and the Rights Agent",
"Stockholder Voting Agreement, by and between Forest Laboratories, Inc. and Fredric N. Eshelman, Pharm.D. and certain affiliates of Dr. Eshelman",
"Revenue Rights Purchase Agreement, by and between Forest Laboratories, Inc. and RPI Finance Trust",
"Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology Deal Also Includes Up to $30 per share in a Contingent Value Right for Furiex Shareholders Creates a Leading GI Company within Forest - Acquisition Adds Global Rights to Eluxadoline - New Drug Application Expected to be Filed in 2014 - Eluxadoline is Complementary to Linzess for IBS-C and CIC and Additive to Forest's GI Treatments Acquired in Acquisition of Aptalis Forest to Partner with Royalty Pharma by Divesting Furiex's Royalty",
"E-mail, from Brenton L. Saunders, the Chief Executive Officer of Forest Laboratories, Inc., to employees of Forest Laboratories, Inc",
"Investor Presentation" |
|
02/19/2014 |
8-K
| Amended existing or entered into new employment agreement with an officer |
02/18/2014 |
8-K
| Investor presentation |
02/03/2014 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs:
|
"Indenture for the 4.375% Senior Notes, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Indenture for the 4.875% Senior Notes, between Forest Laboratories, Inc., as issuer, and Wells Fargo Bank, National Association, as trustee",
"Registration Rights Agreement, by and among Forest Laboratories, Inc., as issuer, and Morgan Stanley & Co. LLC, as representative of the initial purchasers",
"Forest Laboratories, Inc. Completes $2.9B Acquisition of Aptalis" |
|
01/27/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
01/27/2014 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits
Docs:
|
"Consent of PricewaterhouseCoopers LLP",
"Disclosures regarding Forest Laboratories, Inc",
"Forest Laboratories, Inc. Announces Private Placement of Senior Notes Release Date:",
"Audited consolidated balance sheets of Aptalis Holdings, Inc., as of September 30, 2013 and 2012, and the related consolidated statements of income, comprehensive income, stockholders' equity and cash flows for each of the three years in the period ended September 30, 2013, including the notes thereto, and Schedule II",
"Unaudited pro forma combined statements of operations for the six months ended September 30, 2013 and for the year ended March 31, 2012, unaudited pro forma combined balance sheet as of September 30, 2013, and the accompanying notes" |
|
01/21/2014 |
8-K
| Quarterly results |
01/15/2014 |
8-K
| Entry into a Material Definitive Agreement |
01/08/2014 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs:
|
"Agreement and Plan of Merger, by and among FRX Churchill Holdings, Inc., FRX Churchill Sub, Inc., Forest Laboratories, Inc. and Aptalis Holdings, Inc",
"Commitment Letter, among Forest Laboratories, Inc. and Morgan Stanley Senior Funding, Inc",
"Forest Laboratories to Acquire Aptalis for $2.9 Billion in Cash Acquisition is Immediately Accretive - Adds Nearly $700 million to FY2015 Revenues - Company Expects to Achieve $125 Million in Synergies by FY2016 - Accretive to FY2015 Non-GAAP EPS by Approximately $0.78 Diversifies Forest Offerings in Key Therapeutic Areas & Geographies" |
|
12/11/2013 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
12/05/2013 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
12/02/2013 |
8-K
| Form 8-K - Current report |
10/22/2013 |
8-K
| Quarterly results |
10/04/2013 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
06/11/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"Nomination and Standstill Agreement by and between Forest Laboratories, Inc., Carl C. Icahn, Vincent J. Intrieri, High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners LP, Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Enterprises G.P. Inc., Icahn Enterprises Holdings L.P., IPH GP LLC, Icahn Capital LP, Icahn Onshore LP, Icahn Offshore LP, and Beckton Corp",
"FOREST LABORATORIES APPOINTS NEW INDEPENDENT DIRECTOR Vincent J. Intrieri Joins Expanded, 11-Member Board" |
|
04/23/2013 |
8-K
| Quarterly results |
01/15/2013 |
8-K
| Quarterly results |
10/23/2012 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs:
|
"Amendment No. 1 to the Credit Agreement dated December 7, 2007, by and among Forest Laboratories, Inc., Forest Laboratories Holdings Limited, Forest Laboratories Ireland Limited, Forest Finance B.V., Forest Laboratories UK Limited, the lenders party thereto, and JPMorgan Chase Bank, N.A" |
|
10/19/2012 |
8-K
| Quarterly results |
08/28/2012 |
8-K
| Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I... |
07/18/2012 |
8-K
| Quarterly results |
05/11/2012 |
8-K
| Form 8-K - Current report |
04/17/2012 |
8-K
| Quarterly results |
|
|
|